Cell Therapeutics, Inc. (CTIC), Monday said its Pixuvri has been granted market access, by the Transparency Commission of the French National Health Authority. Pixuvri is to be used as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma or NHL.
Cell Therapeutics further said that the next and the final step in France's pharmaceutical reimbursement process is inclusion on the list of medicines approved for hospital use and subsequent publication in the Journal Officiel in France, which it intends to pursue.
The Transparency Commission said that the aggressive NHL is a serious disease and that there are no standard treatments for patients with this stage of disease.
"We are pleased to receive the CT's favorable opinion for reimbursement of PIXUVRI and look forward to bringing this new approved therapy to patients in France with aggressive NHL," said James Bianco, President and CEO.
by RTT Staff Writer
For comments and feedback: email@example.com